
    
      The purpose of this trial is to determine whether isoniazid (INH) reduces the risk of
      Mycobacterium tuberculosis (MTB) infection in HIV-exposed but uninfected (HEU) children, as
      well as to determine epidemiologic and immunologic correlates of MTB infection in HEU.
    
  